Skip to main content
. 2006 Sep 7;116(10):2717–2726. doi: 10.1172/JCI25052

Figure 7. TAT-PNP PTD treatment for 24 weeks normalizes immune function and survival of PNP–/– mice.

Figure 7

Twenty-two PNP–/– mice were injected i.p. twice weekly with 0.5 U/g body wt of TAT-PNP for 24 weeks. Immune function and survival following treatment were not significantly different than those of normal control littermates. (A) Analysis of thymus populations was performed by flow cytometry. Single-cell suspensions from thymi were stained with PE- and FITC-conjugated anti-CD4 and anti-CD8 mAbs. The numbers of total and double-positive thymocytes in thymi of PNP–/– mice after treatment with TAT-PNP were not significantly different than in normal control littermates. (B) Function of T lymphocytes. T lymphocytes isolated from the spleen or lymph nodes were stimulated in vitro with anti-CD3. Response is expressed as stimulation indexes of the mean cpm with stimulation relative to that without stimulation. The stimulation indexes of lymphocytes isolated from PNP–/– mice after 24 weeks of TAT-PNP treatment were not significantly different from those of normal control littermates. (C) Survival of PNP–/– mice treated for 24 weeks with TAT-PNP PTD (n = 22) or a similar volume of PBS (n = 20) and of normal control littermates (n = 30) calculated by the Kaplan-Meier method. Survival of PNP–/– mice after 24 weeks of TAT-PNP treatment (77.3%) was similar to that of normal controls (93.3%) and significantly better than that of PBS-treated PNP–/– mice. #P < 0.001.